« Return to News | Awards & Advancement

Actinium Pharmaceuticals strengthens management team

Thursday, August 30, 2012 02:44 PM

Actinium Pharmaceuticals (API), a private biopharmaceutical company in New York that develops innovative targeted radio-immunotherapeutics, has strengthened its management team with the appointment of Jack V. Talley as president and CEO and Enza Guagenti as CFO.

Talley has more than 30 years of experience in marketing, drug development and regulatory matters. He is responsible for guiding two prior companies, Penwest Pharmaceuticals and EpiCept, through the transition to becoming public reporting entities, where until recently he served as president and CEO. Additionally, Talley oversaw the approval of Ceplene for the remission maintenance of acute myeloid leukemia in the E.U. as well as its license and eventual sale to Meda.

Guagenti is a CPA with over 25 years of experience in health care management financial oversight. Prior to assuming the role of CFO, she worked for API as a corporate accounting consultant for the past eight years. Guagenti has held senior management positions for various companies where she was responsible for operational and financial oversight and reporting, as well as compliance with state and federal regulatory bodies. Guagenti has also served on various state healthcare committees.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.